- BMI ≥ 30, or ≥ 27 with weight-related comorbidity (obesity indication)
- BMI ≥ 30 plus AHI ≥ 15 on a sleep study (OSA indication)
- Documented step therapy or contraindication usually required
- Correct ICD-10 codes prevent the majority of procedural denials
Which indication to submit under
Zepbound has two FDA-approved indications, and your plan may cover one but not the other. Submitting under the wrong indication is the single most common cause of denials on plans that exclude weight-loss drugs.
Obesity: BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity. Submit under E66.01/E66.9 plus comorbidity codes.
Moderate-to-severe OSA (added Dec 2024): BMI ≥ 30 plus AHI ≥ 15 on a recent sleep study. Submit under G47.33 plus E66.01. Many plans that exclude anti-obesity drugs cover Zepbound under the OSA indication.
Clinical criteria most plans require
Adult age (18+), with adolescent extension on some plans.
BMI measured and documented within the last 6 months.
Comorbidity diagnosis confirmed by chart notes (T2D with A1c, HTN with BP readings, OSA with sleep study, dyslipidemia with lipid panel).
Documented prior weight-management interventions: ≥ 3–6 months of lifestyle modification plus prior anti-obesity medication trials (or documented contraindication).
Prescriber attestation that the patient will continue lifestyle modification alongside Zepbound.
Documentation checklist
Most recent height, weight, BMI with date of measurement.
ICD-10 codes for obesity and all qualifying comorbidities.
Sleep study report (for OSA submissions) with AHI ≥ 15.
Chart notes from at least two visits showing weight history.
Prescription records or chart notes documenting prior anti-obesity drug trials (phentermine, orlistat, Contrave, Qsymia) with dates and outcomes.
Letter of medical necessity from the prescriber.
Lab results: A1c, lipid panel, liver function (last 12 months).
ICD-10 codes that prevent procedural denials
E66.01 — morbid (severe) obesity due to excess calories. Use for BMI ≥ 40, or ≥ 35 with comorbidity.
E66.9 — obesity, unspecified. Use for BMI 30–39.9 without the severe modifier.
Z68.30–Z68.45 — BMI category codes. Always pair with E66.xx.
G47.33 — obstructive sleep apnea (adult). Required for the OSA indication.
E11.x — type 2 diabetes (as comorbidity).
I10 — essential hypertension (as comorbidity).
E78.5 — hyperlipidemia (as comorbidity).
Step therapy: what counts and what doesn't
Most plans accept any of the following as satisfying step therapy: ≥ 3 months of documented phentermine; ≥ 3 months of orlistat; ≥ 3 months of Contrave (naltrexone/bupropion); ≥ 3 months of Qsymia (phentermine/topiramate); documented contraindication to all of the above (e.g., uncontrolled HTN for phentermine, pregnancy plans for Qsymia). A documented intolerance or treatment failure is equivalent to a completed trial — the patient does not need to be currently taking the prior drug.
Re-authorization at month 6
Almost all plans require a re-authorization at 6 months. The standard threshold is ≥ 5% reduction from baseline body weight. If you have not reached 5%, the appeal options are: document dose titration history (Zepbound is titrated over 4–5 months, so a slow titration leaves limited time at therapeutic dose), document adherence, and identify clinical factors slowing weight loss (other medications, hypothyroidism, etc.) that warrant continued treatment.
Frequently asked questions
Get a Zepbound PA checklist for your plan
Answer a few questions about your plan and clinical profile — receive a personalized prior-authorization checklist and approval-likelihood score.
Educational guidance only — not medical or legal advice.